Have Questions?

Global Headquarters

Tel: +44 (0)20 7377 0800
Fax: +44 (0)20 7349 5157

North America

Tel: 1-617-573-9450
Fax: 1-617-573-9542

Japan

Tel: +81 (0)80-1164-4754

Request a Demo

What our customers are saying

When I think of the future, I think of EvaluatePharma

Senior Director,
Global pharmaceutical company

EP Vantage Pharma & Biotech 2015 in Review

EP Vantage Pharma & Biotech 2016 in Review EP Vantage Pharma & Biotech 2016 in Review EP Vantage Pharma & Biotech 2016 in Review

Download Report

EP Vantage Pharma & Biotech 2015 in Review

Download Pharma and Biotech 2015 in Review, the new report from our editorial team EP Vantage, which shows that funding for early stage biopharma research dwindled in 2015, as investors shifted their support to more mature companies.

This report is released in conjunction with EP Vantage MedTech 2015 in Review ; both reports offer analysis and expert commentary on M&A deals, venture financing, initial public offerings and FDA approvals in the pharma and medtech sector in 2015.

This latest report offers analysis and expert commentary on M&A deals, venture financing, initial public offerings and FDA approvals in the pharma sector in 2015.

Key Highlights in Pharma & Biotech 2015 in Review:

  • Drug pricing and sustainability issues took the air out of the biotech bubble, leading to the early 2016 market collapse, which negated almost all stock price gains since mid-2014
  • A shift toward mega investment rounds became evident in the pharma & biotech world
  • Top-ten, triple digit venture capital raises consumed nearly one quarter of all available funds for development stage biotechs
  • Pharma & Biotech FDA approvals jumped from an unprecedented 50 in 2014, to 57 in 2015

Press Release


Confirm your details on form below to download this report